Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 5/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18081911 | 0.86 | EP300 (0.38) | EP300MPO | |
| SCHEMBL18080382 | 0.85 | — | — | |
| SCHEMBL18080371 | 0.85 | MAOA (0.34) | EP300 | |
| SCHEMBL18080369 | 0.84 | MPO (0.48) | MPO | |
| SCHEMBL16631482 | 0.83 | EP300 (0.40) | EP300MPO | |
| SCHEMBL18080403 | 0.82 | EP300 (0.36) | EP300 | |
| SCHEMBL18080404 | 0.80 | KCNMA1 (0.52) | MPO | |
| SCHEMBL18080380 | 0.79 | NOTUM (0.46) | — | |
| SCHEMBL22327308 | 0.78 | CDK1 (0.33) | — | |
| SCHEMBL18080375 | 0.77 | RET (0.41) | EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | EP300 4033/4885MPO 2859/4885LOXL2 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.